Roche announced the expansion of its digital pathology open environment with the integration of more than 20 advanced artificial intelligence, or AI, algorithms from eight new collaborators. These strategic collaborations aim to support pathologists and scientists in cancer research and diagnosis by leveraging AI technology. The integration is facilitated through Roche’s navify Digital Pathology enterprise software, an application for the pathologist’s workflow, which now incorporates a range of AI-driven algorithms, creating access to third-party innovation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Poseida Therapeutics initiates P-BCMA-ALLO1 Phase 1b trial
- Roche to present data for fenebrutinib from Phase II FENopta OLE study
- Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
- Trinity Biotech names Adrian Donohue as Chief Commercial Officer
- Truist biotech analysts hold an analyst/industry conference call